Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB – Get Free Report)’s share price passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $6.70 and traded as high as $9.00. Hemispherx BioPharma shares last traded at $6.70, with a volume of 7,639 shares changing hands.
Hemispherx BioPharma Trading Down 20.0%
The firm has a 50-day simple moving average of $6.70 and a 200-day simple moving average of $6.70.
About Hemispherx BioPharma
Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) is a U.S.-based biopharmaceutical company focused on the development and commercialization of immunotherapeutic products for the treatment of viral infections, cancers and immune system disorders. The company’s research centers on harnessing the body’s innate immune response to address diseases that currently lack broadly effective treatments.
Hemispherx’s principal commercial product is Alferon N Injection, an antiviral drug indicated for the treatment of external genital warts.
Read More
- Five stocks we like better than Hemispherx BioPharma
- Is THIS the Next Big Money Rush?
- Wall Street Legend Names #1 Stock of 2026 Live On-Camera
- ISPC: From Small Cap to Life Sciences Market Disruptor!
- The Crash Has Already Started (Most Just Don’t See It Yet)
- INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
